Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Innovators Employ Labyrinthine Defenses To Fend Off Biosimilars

Executive Summary

Innovators are using increasingly complicated tactics in the high-stakes game of keeping biosimilars at bay to ensure their brand-name medicines can keep hauling in the cash for as long as possible.

Advertisement

Related Content

Novartis/Sandoz Biosimilar Erelzi OK'd; Covets Enbrel's US Sales
Pfizer/Celltrion Prep For October Inflectra Launch
Tentative-Style Approvals Coming For US Biosimilars?
Congress Last Resort On IPRs After Supreme Court Backs Patent Board
AbbVie Foe Coherus Sways PTAB To Review Humira Patent
BIO: Deals, Investment At Risk If IPR Course Unchanged
Celltrion/Pfizer Inflectra Second US Biosimilar; Many Firsts
Lawsuit: Sandoz Copycat Piggybacks Enbrel, Ducks Duties
1st U.S. Biosimilar Arrives: Zarxio Launches; Legal Saga Ongoing

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097142

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel